Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$66.60 USD

66.60
1,644,379

+0.71 (1.08%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.

BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 18.33% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?

by Zacks Equity Research

BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Ekta Bagri headshot

Novartis (NVS) to Report Q1 Earnings: What to Expect?

by Ekta Bagri

Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.

Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?

by Zacks Equity Research

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 8.20% and 73.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales

by Zacks Equity Research

BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.

Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings

by Zacks Equity Research

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 11.36% and 1.49%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Nalak Das headshot

5 Stocks Likely to Gain on Q4 Earnings Today After Market Close

by Nalak Das

We have narrowed our search to five large-cap stocks that are poised to beat on earnings today after market closes. These are: BKNG, AMH, FND, BMRN, PBA.

Ekta Bagri headshot

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

by Ekta Bagri

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Clues to BioMarin (BMRN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for BioMarin (BMRN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.

Kinjel Shah headshot

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

by Kinjel Shah

Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.

GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?

by Zacks Equity Research

We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.

Here's Why Investors May Bet on BioMarin (BMRN) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.